Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 19Breast Neoplasms 12Lung Neoplasms 10Brain Neoplasms 9Glioblastoma 7Neoplasm Metastasis 6Neoplasms 5Glioma 5Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 5Sarcoma 4Pancreatic Neoplasms 4Head and Neck Neoplasms 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Mycosis Fungoides 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Liver Neoplasms 3Gliosarcoma 3Waldenstrom Macroglobulinemia 2Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Sezary Syndrome 2Rectal Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Neuroendocrine Tumors 2

Interventions

pembrolizumab 1Magnetic Resonance Spectroscopy 1Ferrosoferric Oxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lung Carcinoma Metastatic in the Brain × Magnetic Resonance Spectroscopy × Clear all
NCT03325166 2022-08-10

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

OHSU Knight Cancer Institute

Phase 2 Terminated
2 enrolled 8 charts

Lung Carcinoma Metastatic in the Brain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡